103 terminated. 103 Phase 1, 30 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 103 | Terminated 103 |
| Phase 2 | 30 | Terminated 30 |
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) TQ05105 tablets, TQB3909 tablets - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 21 | 2024-05-13 | 2026-01-05 |
| TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients TQ05105 Tablets - Myelofibrosis | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 9 | 2022-08-01 | 2025-08-29 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies PRT1419, Azacitidine, Venetoclax - Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 21 | 2022-03-22 | 2024-01-31 |
| Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms Fedratinib Pill - Myeloproliferative Neoplasm | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2022-03-14 | 2025-12-04 |
| Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP) Fedratinib Oral Capsule 300 mg, Decitabine 20 mg/m2, Fedratinib Oral Capsule 400 mg - Myeloproliferative Neoplasm | Phase 1 | Terminated | Joseph Jurcic | 2 | 2022-01-28 | 2024-04-23 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Jaktinib, azacitidine - Myelodysplastic Syndromes, Myeloproliferative Neoplasms | Phase 1 / Phase 2 | Terminated | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 1 | 2021-09-30 | 2022-12-01 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis Mivebresib, Navitoclax, Ruxolitinib - Myelofibrosis (MF) | Phase 1 | Terminated | AbbVie | 1 | 2021-03-17 | 2023-08-29 |
| Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients Bosutinib 400 MG Monotherapy, Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection - Chronic Phase-Chronic Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica | 9 | 2021-02-24 | 2024-03-19 |
| Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia Cytarabine, Filgrastim, Fludarabine - Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome | Phase 1 | Terminated | Northwestern University | 2 | 2020-12-21 | 2026-06-01 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
| Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Eicosapentaenoic Acid, Tyrosine kinase inhibitor - Chronic Myeloid Leukemia, Chronic Phase | Phase 1 / Phase 2 | Terminated | Milton S. Hershey Medical Center | 1 | 2020-09-14 | 2022-07-01 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 45 | 2019-09-26 | 2025-08-07 |
| Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib PU-H71 - Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Phase 1 | Terminated | Samus Therapeutics, Inc. | 11 | 2019-08-12 | 2022-11-17 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Allogeneic Hematopoietic Stem Cell Transplantation, Liposome-encapsulated Daunorubicin-Cytarabine, Ruxolitinib - Essential Thrombocythemia, Myelofibrosis | Phase 1 / Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 12 | 2019-02-20 | 2026-04-24 |
| IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT Fludarabine, Total Marrow Irradiation (TMI) - Acute Myeloid Leukemia, Chronic Myeloid Leukemia | Phase 1 | Terminated | Naoyuki G. Saito, M.D., Ph.D. | 6 | 2018-08-29 | 2022-03-09 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia Dexamethasone, Ponatinib Hydrochloride, Rituximab - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2018-06-26 | 2025-05-08 |
| Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis PU-H71, Ruxolitinib - Myelofibrosis, Primary Myelofibrosis | Phase 1 | Terminated | Samus Therapeutics, Inc. | 4 | 2018-05-24 | 2022-11-15 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
Showing 20 of 103. Sign in to see all of them.
Leukemia, Myeloid, Acute (55) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (42) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (41) · Myelodysplastic Syndromes (37) · Primary Myelofibrosis (29) · Blast Crisis (24) · Leukemia (24) · Congenital Abnormalities (23) · Leukemia, Lymphocytic, Chronic, B-Cell (22) · Multiple Myeloma (18) · Lymphoma (15) · Lymphoma, Non-Hodgkin (15) · Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, Mantle-Cell (14)
Bone Marrow Diseases (103) · Hemic and Lymphatic Diseases (103) · Hematologic Diseases (102) · Neoplasms (91) · Neoplasms by Histologic Type (87) · Leukemia, Myeloid (78) · Chronic Disease (72) · Disease Attributes (72) · Pathologic Processes (72) · Pathological Conditions, Signs and Symptoms (72) · Leukemia (61) · Immune System Diseases (53) · Immunoproliferative Disorders (53) · Lymphatic Diseases (52)
ruxolitinib (11) · Cytarabine (10) · Dasatinib (8) · Azacitidine (6) · Imatinib Mesylate (6) · fludarabine (5) · Alemtuzumab (4) · Busulfan (4) · Cyclophosphamide (4) · Etoposide (4) · Mitoxantrone (4) · Arsenic Trioxide (3) · Cyclosporine (3) · Decitabine (3) · Melphalan (3)
National Cancer Institute (NCI) (11) · M.D. Anderson Cancer Center (7) · Incyte Corporation (6) · Masonic Cancer Center, University of Minnesota (5) · Merck Sharp & Dohme LLC (4) · Exelixis (3) · Fred Hutchinson Cancer Center (3) · Novartis Pharmaceuticals (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Astex Pharmaceuticals, Inc. (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · City of Hope Medical Center (2) · Gilead Sciences (2) · Milton S. Hershey Medical Center (2) · Northwestern University (2)
United States (87) · Canada (7) · France (6) · Spain (5) · Belgium (4) · Italy (4) · China (3) · Germany (3) · South Korea (3) · United Kingdom (3) · Australia (2) · Denmark (2) · Hungary (2) · Netherlands (2) · Russia (2)
Roger Strair, MD, PhD (3) · Farhad Ravandi-Kashani (2) · Fred Zheng, M.D. (2) · Jan Cerny, MD, PhD (2) · Abhinav Deol, M.D. (1) · Akil Merchant, MD (1) · Alex Adjei (1) · Allen R. Chen, MD,PhD. MHS (1) · Amy Hobeika, PhD (1) · Andrew Artz, M.D. (1) · Ann E. Woolfrey, MD (1) · Ann Mohrbacher (1)
PMID 31527168, PMID 17151364, PMID 19010875, PMID 19029442, PMID 19139736, PMID 19503090, PMID 20460644, PMID 20563869, PMID 21145590, PMID 22080968, PMID 22987312, PMID 23092873, PMID 23256542, PMID 23393050, PMID 23682558, PMID 24355079, PMID 30962222, PMID 33451977, PMID 34951522, PMID 35176457, PMID 36841672, PMID 37290996, PMID 39863139, PMID 39929221, PMID 40334082, PMID 40752760
2017 (3), P30CA072720 (3), N01CM62203 (2), U01CA076576 (2), 2019 (1), N01CM00032 (1), N01CM00100 (1), P01CA018029 (1), P01CA070970 (1), P30CA006973 (1), P30CA014089 (1), P30CA015704 (1), P30CA016672 (1), P30CA033572 (1), P30CA046934 (1)